Litcius/Paper detail

Medicinal herbs and bioactive compounds overcome the drug resistance to epidermal growth factor receptor inhibitors in non‑small cell lung cancer (Review)

Hiu Lee, Mingjing Meng, Yulong Liu, Tao Su, Hiu Yee Kwan

2021Oncology Letters28 citationsDOIOpen Access PDF

Abstract

Lung cancer is the leading cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for ~85% of all lung cancer cases. Patients harboring epidermal growth factor receptor (EGFR) mutations usually develop resistance to treatment with frontline EGFR-tyrosine kinase inhibitors (EGFR-TKIs). The present review summarizes the current findings and delineates the molecular mechanism of action for the therapeutic effects of herbal extracts and phytochemicals in overcoming EGFR-TKI resistance in NSCLC. Novel molecular targets underlying EGFR-TKI resistance in NSCLC are also discussed. This review provides valuable information for the development of herbal bioactive compounds as alternative treatments for EGFR-TKI-resistant NSCLC.

Topics & Concepts

Epidermal growth factor receptorLung cancerMedicineMolecular medicineCancerOncogeneCell cyclePharmacologyTyrosine kinaseCancer researchDrug resistanceEGFR inhibitorsTreatment of lung cancerOncologyInternal medicineBiologyReceptorMicrobiologyLung Cancer Treatments and MutationsCancer Mechanisms and TherapySynthesis and biological activity